Grants and Giving
Supports evidence-based educational programs to enhance clinical decision-making in ATTR-CM for healthcare professionals, emphasizing practical, real-world impact through symposia, digital CME, and live events.
Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (full proposal submission)
Funding Amounts: Up to $250,000 per proposal; multiple awards possible; actual award may vary from request.
Summary: Supports independent educational initiatives to advance clinical decision-making in transthyretin-mediated amyloidosis (ATTR-CM), with emphasis on practical, real-world impact for healthcare professionals.
Key Information: Applicants must be organizations (not individuals); ACCME accreditation required for medical education providers.
Description
Alnylam Pharmaceuticals is soliciting proposals for independent educational initiatives focused on improving clinical decision-making in transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). This opportunity, posted as RFP ALNY-RFP-TTR-13, aims to address persistent gaps in the screening, diagnosis, monitoring, and management of ATTR-CM, particularly through practical, actionable content for healthcare professionals. Supported programs should be evidence-based, facilitate real-world application, and may target both U.S. and global audiences. Funding is available for educational symposia at major cardiology congresses, digital CME platforms, and regional live programs.
